Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Exchange Traded Concepts LLC lowered its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 55.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,981 shares of the company’s stock after selling 32,241 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Structure Therapeutics were worth $1,807,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Balyasny Asset Management L.P. acquired a new position in shares of Structure Therapeutics during the third quarter worth approximately $12,923,000. Orbimed Advisors LLC grew its stake in shares of Structure Therapeutics by 49.5% in the second quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company’s stock worth $24,873,000 after acquiring an additional 397,272 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new position in Structure Therapeutics during the third quarter worth $10,440,000. Casdin Capital LLC raised its stake in Structure Therapeutics by 26.9% during the 3rd quarter. Casdin Capital LLC now owns 1,555,000 shares of the company’s stock valued at $43,540,000 after purchasing an additional 330,000 shares during the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in Structure Therapeutics during the 3rd quarter valued at $6,856,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $50.17 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $13.22 and a 52-week high of $94.90. The firm has a market capitalization of $3.55 billion, a PE ratio of -63.51 and a beta of -1.16. The company’s fifty day moving average price is $66.17 and its two-hundred day moving average price is $52.16.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on GPCR. Morgan Stanley raised their price target on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Citizens Jmp cut their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a research report on Friday, February 27th. HC Wainwright decreased their target price on Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, March 16th. Citigroup restated an “outperform” rating on shares of Structure Therapeutics in a research note on Friday, December 12th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.00.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.